Product Information

LEGEND® Injectable Solution is indicated in the treatment of joint dysfunction of the carpus or fetlock in horses due to non-infectious synovitis associated with equine osteoarthritis.

LEGEND delivers proven efficacy

In field studies, overall clinical improvement was judged to be excellent or good in 90% of the cases treated intravenously with LEGEND and 96% of those treated intra-articularly with LEGEND.1
By decreasing the production and release of inflammatory mediators, LEGEND helps reduce joint inflammation and the resulting pain and lameness.2

The interleukin-1-driven production and release of prostaglandin and also the protein count in synovial fluid is decreased for 45 days following I.V. injection, indicating a beneficial effect long after I.V. administration.


The Properties of Hyaluronic Acid (HA)

HA stimulates endogenous HA production.

HA administration stimulates synoviocytes to produce endogenous high-molecular-weight HA.3

HA provides a physical barrier.

HA contributes to the steric exclusion of plasma components and leukocytes.2

HA decreases the presence of inflammatory mediators.

HA decreases the interleukin-1-driven production and release of prostaglandin E2. PgE2 causes cartilage destruction.4 HA scavenges oxygen-derived free radicals.5

LEGEND is pure hyaluronic acid

Derived naturally through a unique biofermentation process, LEGEND is pure hyaluronic acid. After biofermentation, LEGEND is purified through a 12-step microfiltration process to remove impurities and foreign proteins. Foreign proteins increase the potential for joint flares.

Therapeutic objective

The primary objective of equine joint therapy should be to block the further release of inflammatory mediators while decreasing the effect of the mediators already released.

Treat non-infectious synovitis with the proven performance of LEGEND®

  • The FDA-approved joint therapy for both I.V. and I.A. administration, so you can choose the treatment to meet the horse's needs
  • Produced through biofermentation and purified though a 12-step microfiltration process to help reduce the presence of foreign proteins
  • By decreasing the production and release of inflammatory mediators, LEGEND helps reduce joint inflammation and the resulting pain and lameness.2
  • LEGEND is backed by extensive independent university studies and research.
  • Up to three once weekly I.V. doses of LEGEND will treat all affected fetlocks and carpi of the horse.

mediators of inflammation penetrating the synovial membraneThis image shows mediators of inflammation penetrating the synovial membrane to cause cartilage damage. HA decreases the presence of the mediators of inflammation.
arrow Learn More

IMPORTANT SAFETY INFORMATION:
Click here to view the complete label and usage instructions.

Federal law restricts this drug to use by or on the order of a licensed veterinarian. For use only in horses. Do not use in horses intended for human consumption.

LEGEND 4 mL and LEGEND® Multi dose 20 mL are approved only for I.V. use. LEGEND 2 mL is approved for I.V. and I.A. use. The intra-articular safety of LEGEND Multi Dose with benzyl alcohol has not been evaluated.

The safety of LEGEND has not been evaluated in breeding stallions or in breeding, pregnant or lactating mares.

Not for use in humans. Keep this and all other drugs out of reach of children. Strict aseptic techniques should be observed when administering by intra-articular injection.

Post-Approval Experience: While all adverse reactions are not reported, the following adverse reactions are based on voluntary post-approval reporting for Legend Injectable Solution: Following intravenous use: Occasional depression, lethargy and fever. Following intra-articular (Legend Injectable Solution - 2 mL only) use:lameness, joint effusion, joint or injection site swelling, and joint pain.

1. Freedom of Information Summary for LEGEND (hyaluronate sodium) Injectable Solution. NADA 140-883.
2. Kawcak, CE; Frisbee, DD; Trotter, GW; McIlwraith, CW; Gillette, SM; Powers, BE; Walton, RM: Effects of intravenous administration of sodium hyaluronate on carpal joints in exercising horses after arthroscopic surgery and osteochondral fragmentation. AJVR 1997; 58(10): 1132-1140.
3. Smith, M.M.;Ghosh, P.: The synthesis of hyaluronic acid by human synovial fibroblasts is influenced by the nature of the hyaluronate in the extracellular environment. Rheumatol Int. 1987;7(3):113-22. .
4. Lipiello L. Yamamoto K, Robinson D, et al: Involvement of prostaglandins from rheumatoid synovium in inhibition of articular cartilage metabolism. Arthritis Rheum. 1978; 21:909-917.
5. Sato H, Takahashi T, Ide H, et al. Antioxidant activity of synovial fluid, Hyaluronic acid and two subcomponents of hyaluronic acid. Arthritis Rheum 1988:31:63-71.